Novo Nordisk has launched NovoCare® Pharmacy, an initiative aimed at enhancing affordability and access to its FDA-approved weight management drug, Wegovy® (semaglutide). The program reduces the monthly cost to $499 for all doses and provides convenient home delivery for cash-paying patients. According to Dave Moore, Executive Vice President of U.S. Operations and Global Business Development at Novo Nordisk, over 55 million people in the U.S. have coverage for weight management medicines, with 90% of insured Wegovy® patients paying between $0 to $25 monthly. NovoCare® Pharmacy ensures that patients receive authentic, FDA-approved Wegovy®, avoiding risks associated with compounded medications. The service also includes benefits such as benefit verification, refill reminders, and live support from NovoCare® case managers. Home deliveries are fulfilled by CenterWell Pharmacy, recognized for its customer satisfaction. In the future, Novo Nordisk plans to extend these savings to cash-paying patients using traditional retail pharmacies. More information is available at NovoCare.com and semaglutide.com. — news from PR Newswire
